December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

167.55 -3.14 (-1.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
23 24 Next >
News headline image
How Is The Market Feeling About Axsome Therapeutics? ↗
Axsome Therapeutics's (NASDAQ:AXSM) short percent of float has fallen 7.06% since its last report. The company recently reported that it has 7.37 million shares sold short, which is 20.81% of all... 
Via Benzinga
News headline image
100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles ↗
Energy and medical plays top the 100 Best Stocks of 2022. It makes sense, given world events that shifted the first-quarter playing field. 
Via Investor's Business Daily
News headline image
2 Growth Stocks to Buy Heading Into 2023 ↗
These biotechs are far from having achieved their full potential. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
2 Top Biotech Stocks to Buy for the Long Haul ↗
These mid-cap biotechs are solid long-term choices. 
Via The Motley Fool
Here's How Much $100 Invested In Axsome Therapeutics 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $1,500 Today ↗
 
Via Benzinga
News headline image
Axsome Therapeutics Stock: Bear vs. Bull ↗
2023 will almost certainly see Axsome's top line explode higher. 
Via The Motley Fool
News headline image
Got $5,000? 2 Unstoppable Stocks to Buy and Hold ↗
These businesses are growing and can be excellent places to make a sizable investment right now. 
Via The Motley Fool
News headline image
Better Buy: Moderna vs Axsome ↗
Revenue prospects look promising for both of these biotech companies. 
Via The Motley Fool
News headline image
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond ↗
Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year. 
Via InvestorPlace
News headline image
Should You Buy Stocks If a Recession Is Coming in 2023? Here's What History Shows. ↗
Stocks usually go down during recessions, but long-term investors can still come out on top. 
Via The Motley Fool
News headline image
After Jumping 100%, Is Axsome a Buy Before 2023? ↗
Axsome's revenue story is just getting started. 
Via The Motley Fool
News headline image
Is Anavex Life Sciences a Buy? ↗
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's. 
Via The Motley Fool
Axsome Therapeutics's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Where to Invest $1,000 Before the End of 2022 ↗
Right now is the perfect time to put your money to work. 
Via The Motley Fool
News headline image
3 High-Flying Stocks to Buy and Hold If a Recession Is on the Way ↗
An economic downturn shouldn't hurt these stocks. 
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
These Were The Five Best And Worst Performing Mid-Cap Stocks In November 2022 ↗
In November, the Dow Jones gained around 7%, the S&P 500 gained 8.4%, and the Nasdaq gained 9.1%. The S&P Mid-Cap 400 performance was in line with major indices. Let’s take a look at the five best and... 
Via Talk Markets
News headline image
3 Red-Hot Stocks That Could Continue to Beat the Market ↗
The success these stocks achieved in 2022 could be just the beginning. 
Via The Motley Fool
News headline image
3 High-Flying Stocks in 2022 That Should Keep Soaring in 2023 ↗
These stocks' tailwinds should continue blowing in the new year. 
Via The Motley Fool
News headline image
3 Surefire Stocks to End 2022 on a Good Note ↗
These stocks should help your portfolio shine now and well into the future. 
Via The Motley Fool
News headline image
2 Unstoppable Growth Stocks to Buy in 2022 and Beyond ↗
These biotech players beat the bear market this year. 
Via The Motley Fool
News headline image
3 Fierce Stocks That Are Screaming Buys in December ↗
Here are three winners in the making. 
Via The Motley Fool
News headline image
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money ↗
There's no guarantee of 100% returns for these stocks, but their chances look pretty good. 
Via The Motley Fool
News headline image
12 Top Stocks to Buy in December ↗
Add this dandy dozen to your stocking this month. 
Via The Motley Fool
News headline image
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review ↗
The S&P 500 is fighting for its 200-day, a critical level for the uptrend. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that. 
Via MarketBeat
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.